NDAORALTABLET
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
RECORLEV (levoketoconazole) by Bridge Therapeutics is cytochrome p450 11b1 inhibitors [moa]. First approved in 2021.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RECORLEV (levoketoconazole) is an oral tablet approved in December 2021 for the treatment of Cushing's syndrome. It functions as a cytochrome P450 11B1 inhibitor that directly suppresses cortisol synthesis at the adrenal level. This selective mechanism addresses the pathophysiology of cortisol excess by inhibiting the enzyme 11β-hydroxylase, which catalyzes the final step of cortisol production.
$0.0BPart D
13.8 years to LOEMechanism of Action
Cytochrome P450 11B1 Inhibitors
Pharmacologic Class:
Cortisol Synthesis Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RECORLEV supports specialized roles including field medical representatives, key opinion leader engagement specialists, and product managers focused on rare endocrine disorders. Success in this space requires deep knowledge of Cushing's syndrome pathophysiology, familiarity with hospital and specialty pharmacy channels, and ability to engage with endocrinologists and specialized centers. Currently, zero linked job openings are identified, reflecting the early-stage commercialization phase and the niche market focus.
Company
Worked on RECORLEV at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.